HemoPill® acute

Swallowable capsule with optical sensor for the immediate detection of acute bleeding in the oesophagus, stomach, and small intestine. To HemoPill® acute
Category:

Description

+49 7071 96528 160
service@ovesco.com

Range of application of the HemoPill® acute

The HemoPill® acute is a swallowable sensor capsule for the immediate detection of acute bleeding in the oesophagus, stomach and small intestine. The HemoPill® acute sends measured values wirelessly to a portable receiver (HemoPill® Receiver) for blood detection.

The HemoPill® acute

The HemoPill® acute has a measuring gap with optical sensor. The blood is detected by directly measuring blood in the measuring gap. The detection of blood is even possible in an unprepared digestive tract.

The measured values generated by the HemoPill® acute are transmitted wirelessly in real time to the HemoPill® Receiver.

Dimensions and specifications

Length26.3 mm
Maximum diameter7.0 mm
Maximum measuring time9 hours
Packaging unit5 pieces
Reference number500.01

Application of the HemoPill® acute

Step 1: Switch on the HemoPill® Receiver

Step 2: Activate HemoPill® acute in the blister pack using the HemoPill® Receiver

Step 3: Establish a connection between HemoPill® acute and HemoPill® Receiver

Step 4: Take HemoPill® acute with a glass of water

Step 5: Interpret transmitted measured values (HemoPill® Indicator, HI) on the display of the HemoPill® Receiver:
An HI value in the red range of the diagram means that liquid blood (or haematin) has been detected

->positive finding

Step 6: Print out the finding for the patient file if required

Application video

Use case: Positive HemoPill® finding (indication for immediate endoscopy and treatment)

Example 1: Detection of acute bleeding in the stomach

20 minutes after swallowing the HemoPill® acute, a significant increase in the HI value was observed. This indicated acute bleeding in the upper digestive tract. The examination using the HemoPill® was completed after 43 minutes and a gastroscopy was performed immediately. This showed a bleeding angiodysplasia in a gastrojejunal anastomosis, which was successfully treated.

Example 2: Detection of bleeding in the small intestine

The significant increase in the HI value after 2.5 hours was indication of bleeding in the middle digestive tract. The examination took a total of 9 hours. A subsequent targeted double balloon enteroscopy showed angiodysplasia in the small intestine, which was treated successfully.

Use of the HemoPill® acute in the early clinical phase (July 2019 – September 2020)
Source: Prof. Dr. Arthur R. Schmidt and Dr. Armin Kuellmer, Medical Center – University of Freiburg, Germany / Prof. Dr. Juergen Hochberger and Dr. Thomas Brunk, Vivantes Klinikum im Friedrichshain, Germany

Use case: Negative HemoPill® finding (postponing or avoiding emergency endoscopy)

Example 1: Excluding upper GI bleeding

No increase in the HI value was observed after the capsule was swallowed. Further differential diagnostics identified an aortic dissection as the cause of the anaemia detected in the emergency room. This meant that the patient did not need to undergo an endoscopy.

Use of the HemoPill® acute in the early clinical phase (July 2019 – September 2020)
Source: Prof. Dr. Arthur R. Schmidt and Dr. Armin Kuellmer, Medical Center – University of Freiburg, Germany / Prof. Dr. Juergen Hochberger and Dr. Thomas Brunk, Vivantes Klinikum im Friedrichshain, Germany

Media

{{pluginSettings.generalSettings.writing.no_results}}
of {{actionSettings.pagesCount}}

Other products of the HemoPill® product family

TOP